HHS Public Access

Author manuscript
Drugs Aging. Author manuscript; available in PMC 2019 May 01.
Author Manuscript

Published in final edited form as:

Drugs Aging. 2018 May ; 35(5): 399–408. doi:10.1007/s40266-018-0545-3.

A Glimpse into Uveitis in the Aging Eye

Elizabeth Akinsoji, BA1, Raquel Goldhardt, MD, FACS1,2,3, and Anat Galor, MD, MSPH1,2,3
1University of Miami Miller School of Medicine, Miami, FL
2Miami Veterans Administration Medical Center, Miami, FL
3Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL
Author Manuscript

Abstract
Uveitis describes a group of inflammatory conditions of the eye that have various underlying
causes and clinical presentations. Susceptibilities to uveitis in the elderly may be attributed to age-
related risk factors such as immunosenescence, increased immunological inflammatory mediators,
and autoimmunity. Overall anterior uveitis is more common than posterior and panuveitis in the
general population and also in the elderly. Some causes of uveitis in the elderly are herpes simplex
virus (HSV), ocular ischemic syndrome, sarcoidosis, and central nervous system lymphoma and
these will be discussed in detail herein. Eye care professionals need to consider the wide
differential for uveitis, obtain the appropriate history, conduct a detailed clinical examination, and
tailor management to the clinical presentation and underlying cause of disease. The challenges of
polypharmacy and nonadherence in the elderly impact patient outcomes and must be taken into
consideration when considering treatment.
Author Manuscript

1. Introduction
Uveitis is a common cause of legal blindness in both the United States (US) and developing
countries, comprising 10% and 25% of cases respectively.1 Though it most typically affects
patients ages 20 to 60 years, there are subtypes of uveitis that are more common in older
individuals. In addition, developed countries such as the US have a higher mean percentile
of uveitis in comparison to developing countries among the older population (18% versus
7% respectively)1, likely due to the larger elderly population with more access to healthcare
in developed countries.

Uveitis is characterized by inflammatory processes that affect the iris, ciliary body, retina,
Author Manuscript

and/or choroid. The inflammation has several possible etiologies that include autoimmunity,
infections, neoplasms, and toxins.2 Based on the Standardization of Uveitis Nomenclature
(SUN) criteria, uveitis is subtyped by the primary site of inflammation (anterior,
intermediate, posterior, pan-uveitis).3 Structural changes caused by inflammatory processes
(e.g. macular edema and/or neovascularization) are often seen with differing frequency
depending on the uveitis sub-type.

Corresponding author: Anat Galor, MD, MSPH, 900 NW 17th Street, Miami, FL 33136; [email protected].
Compliance with Ethical Standards
No conflicting relationship exists for any author.
 Akinsoji et al. Page 2

The major site of anterior uveitis is the iris and/or ciliary body, which is common in both
younger and middle-aged groups.4 It is also the most common subtype of uveitis in the
Author Manuscript

elderly population.1 Anterior uveitis can be associated with autoimmune disorders as well as
infectious diseases. Intermediate uveitis has most of its inflammation in the vitreous. This
subtype is more common in in younger populations and is associated with sarcoidosis and
multiple sclerosis.5 Posterior uveitis involves the retina, choroid, blood vessels, and optic
nerve. Panuveitis has no predominant site of inflammation and affects all layers of the eye.

Uveitis is further divided by time course. In general, uveitis is characterized as acute if its
time course if less than 3 months; furthermore, once the inflammation is resolved, the
individual is able to stop all medications without a recurrence within a 3 month time frame.
Uveitis is characterized as chronic if its time course is greater than 3 months, and if once
inflammation is controlled and medications are stopped, a recurrence occurs within 3
months.
Author Manuscript

2. Pathophysiology of uveitis in the elderly

2.1. Immunosenescence
There are several reasons why the elderly may be susceptible to certain forms of uveitis.
Immunosenescence is a process where numerous key players of the immune system are
either decreased or negatively altered with age, increasing the elderly’s susceptibility to
infection. For example, hematopoietic stem cells (HSCs), found in bone marrow and
responsible for differentiating into white blood cells, have a decreased ability to
differentiate.6,7 This may occur both because of intrinsic changes in HSCs and because of
changes in the bone marrow environment.6 Regarding the latter, with age there is a reduction
of osteoblasts, cells responsible for secreting osteopontin, a matrix glycoprotein.8 After
Author Manuscript

exposing HSCs to bone marrow stroma that lacked osteopontin, a mice study found that
HSCs had decreased functional abilities.8

White blood cells are primarily divided into innate and adaptive components and both are
affected with aging.9 The innate immune system is the first to act during an infection and
involves macrophages, neutrophils, dendritic cells, and natural killer cells. Although the
innate immune system is quick to respond, it does so in a nonspecific manner.9 Components
of the innate immune system become less effective with age. Macrophages secrete pro-
inflammatory cytokines that help fight extracellular pathogens (e.g. bacteria). With
increasing age, monocyte numbers (macrophage precursors) are reduced and macrophage
function is decreased.9 While the number of neutrophils remains relatively constant with
age, their CD16 Fc-gamma receptor, which facilitates the destruction of extracellular
Author Manuscript

pathogens, is impaired.9 In a similar manner, natural killer cell numbers also remain stable
with age, but their production of interleukin-2 (IL-2), which helps recruit lymphocytes that
destroy intracellular organisms, decreases.9 Dendritic cells, antigen-presenting cells (APC)
which present possible harmful material to lymphocytes for destruction, acquire
mitochondrial dysfunction with age. The latter dysfunction leads to oxidative stress that can
cause deoxyribonucleic acid (DNA) and protein damage, impairing function.10 Furthermore,
several organs such as the skin, mucosa (respiratory and gastrointestinal lining), and hair are

Drugs Aging. Author manuscript; available in PMC 2019 May 01.

 Akinsoji et al. Page 3

important members of the innate immune system as they provide barriers to infection. These
structures often deteriorate (skin thins with age11) or are lost (i.e. hair) with age.9
Author Manuscript

The adaptive immune system is slower to respond but is more specific and effective in
ridding the body of pathogens, especially intracellular organisms (e.g. viruses). It is
composed of lymphocytes (B and T cells) whose proliferative abilities wane with age.12
After being produced in the bone marrow, T cells mature and multiply into 2 main subsets in
the thymus: CD4+ cells which include both helper T cells that facilitate immune cell
recruitment and regulatory T cells that suppress the immune system and CD8+ which are
cytotoxic and help destroy cells affected by intracellular pathogens. CD4+ and CD8+ T cells
that have not encountered a pathogen are called naïve. The population of naïve T cells
declines with age (partly due to shrinkage of the thymus), and they are less able to
differentiate into effector cells,.9 T cells are also less able to produce cytokines such as the
immune signaling molecule IL-2 with age.9,13 Short-lived effector T cells either die or
Author Manuscript

differentiate into memory cells after they have completed their role in an infection.14,15 IL-2
helps prevents cell death, promoting memory cell differentiation.14,16 Long-lived memory T
cells provide “memory” of the infection so that the body can mount a stronger and quicker
response when it encounters a similar infection again.15 Decreased IL-2 secretion leads to a
less robust memory T cell response, contributing to the increased susceptibility of infection
reactivation (such as herpes virus) seen in the elderly.16

Memory T cells also differentiate directly from naïve T cells.14,15 To compensate for the
decline in naïve T cell populations, naïve T cells live for longer periods of time in the
peripheral tissues with increasing age.17,18 This increased survival in the periphery allows
naïve T cells to acquire multiple intrinsic defects over time, interfering with their protective
role.17 One mice study found that memory T cells that differentiated from naïve CD4+ T
Author Manuscript

cells in aged mice had worse memory function than naïve CD4+ T cells differentiated from
young mice.19 Interestingly, although there is general decline of the naïve T cell population
with age, T regulatory cell numbers have been found to increase. These findings also likely
contribute to the elderly’s susceptibility to infection, particularly to reactivation of a chronic
infection.9

B cells are the second type of lymphocytes that play an important in role in adaptive
immunity. They are APCs that present foreign material (or antigens) to T cells. Plasma cells
(activated B cells) also produce antibodies. Antibodies (or immunoglobulins) are large Y-
shaped proteins that have 5 subtypes: IgM, IgD, IgE, IgA, IgG. These subtypes are used to
neutralize pathogens during an infection, and certain types are used depending on the type of
infection. For example, IgA plays a critical role in mucosal immunity.9 Antibodies provide
protection from both extracellular and intracellular pathogens.20 Overall, with age, there is a
Author Manuscript

reduced population of plasma cells in the bone marrow, leading to decreased antibody
production, and increased vulnerability to infection.12 However, the antibodies that are
produced are more frequently autoreactive (as discussed below).21,22

The elderly are also more susceptible to infections and cancer because of the accumulation
of reactive oxygen species (ROS)/free radicals. Apoptosis is a programmed way for cells to
shut down in the event of an uncontrollable accumulation of DNA errors. ROS damage the

Drugs Aging. Author manuscript; available in PMC 2019 May 01.

 Akinsoji et al. Page 4

DNA reparative and restorative processes of cells.9 As such, increased ROS make cells more
resistant to apoptosis and results in mutated and dysfunctional cells.9
Author Manuscript

2.2. Inflammaging
While some cytokine levels are reduced with age (e.g. IL-2), others are increased including
the pro-inflammatory cytokines IL-6, IL-1, and tumor necrosis factor (TNF).23 An
imbalance between players that inhibit the immune system and those that mediate
inflammation is thought to contribute to the pathophysiology of non-infectious uveitis in the
elderly. While increasing levels of IL-6, IL-1, and TNF promote chronic inflammation, the
eye has regulatory molecules and processes that dampen inflammation, such as transforming
factor- beta 2, alpha-melanocyte stimulating hormone, vasoactive intestinal peptide, and Fas
ligand (FasL).24,25 When pro-inflammatory cytokines overwhelm the anti-inflammatory
responses of the eye, the extent of inflammatory damage from an immune response becomes
Author Manuscript

unchecked and can manifest as uveitis.

This upregulation of pro-inflammatory cytokines results in what is termed inflammaging,

which describes the non-infectious, “chronic, low-grade, and systemic inflammation” that
occurs during the aging process and is responsible for many age-related conditions and
diseases, like decreased muscle mass, osteoporosis, Alzheimer’s disease, vascular disorders,
cognitive decline, and vascular dementia.23,26

Senescent cells that increasingly accumulate in adipose tissue with age and secrete pro-
inflammatory markers are thought to underlie inflammaging.23,27 Senescent cells are cells
that no longer divide or proliferate because of damage or dysfunction.23,27 They accumulate
because the body has a decreased ability to clear them with age.23,27 Another source of
inflammaging is an accumulation of debris that occurs from damaged/dysfunctional cells or
Author Manuscript

metabolites such as urate crystals (observed in gout28), which can trigger an inflammatory
immune response.23 If the debris resembles the molecular patterns of foreign antigens
(molecular mimicry), these neo-self antigens induce an autoimmune response.29 Like
senescent cells, self-antigens are cleared less quickly from the body with age and can cause
chronic inflammation.23

As one ages, the immune system is also less able to distinguish between antigens that are
“self” versus “foreign,” which is theorized to lead to a paradoxical overproduction of
autoreactive antibodies in the presence of a declining population of plasma cells.21,22 In a
baboon study, levels of circulating autoantibodies increased from younger to older baboons,
even in the absence of immune pathology.22 The increase in autoreactive antibodies in the
elderly is proposed to result partly from reactivation of memory B cells and accumulation of
Author Manuscript

neo-self antigens as discussed above.29

Increased antibodies leads to increased autoreactive autoantibody-antigen complexes.22,29

When these complexes accumulate at a faster rate than they can be cleared by mononuclear
phagocytes, they start depositing in highly vascular tissues such as the ciliary body or
choroidal plexus of the eye.30 These complexes can block vascular flow and activate the
complement system with subsequent inflammation.30

Drugs Aging. Author manuscript; available in PMC 2019 May 01.

 Akinsoji et al. Page 5

Mitochondria also play a critical role in inflammaging.23 Mitochondrial components (e.g.

Author Manuscript

cardiolipin) resemble foreign pathogens, activating the innate immune system and the pro-
inflammatory signaling pathway called the Nlpr3 inflammasome.23 While its role in uveitis
is unclear, this latter pathway is involved in other eye diseases such as age-related macular
degeneration (AMD).31 Overall, many of the studies above described aging changes that
occur in animal models which is not directly translatable to human disease. However, these
ideas provide insight on the pathogenesis of uveitis in the elderly.

3. Symptoms and course

Patients with uveitis can experience visual disturbances such as blurred vision, floaters, eye
redness, and spontaneous and evoked pain (such as to light). Symptoms profiles vary by
uveitis subtype. For example, individuals with acute anterior uveitis typically report eye
redness and pain, while central vision loss is more common with posterior uveitis.4 Floaters
Author Manuscript

are often the presenting complaint in intermediate uveitis. Uveitis can be described as acute
(lasting < 3 months), persistent (lasting > 3 months), or recurrent (episodes occurring after
periods of inactivity, without treatment for at least 3 months).3 Chronic uveitis is
characterized as persistent with relapses within 3 months after cessation of treatment.

4. Uveitis evaluation
In evaluating a patient for uveitis, ophthalmologists perform an eye exam that includes
visual acuity assessment, intraocular pressure measurement, slit lamp examination, and
fundoscopy. Specifically, ophthalmologists grade the presence of anterior chamber cells and
flare, vitreous cell, vitreous haze (based on clarity of retinal vessels and optic nerve) as well
as document the involvement of posterior structures. The doctor may also note any redness
Author Manuscript

of the eyes and its location. For instance, redness at the limbus (between the region of the
cornea and the sclera) is characteristic of anterior uveitis. A thorough review of systems is
needed to look for systemic manifestations of inflammation or infection. A review of the
medical history and medication list is essential as well. Additional testing is determined by
the clinical presentation and review of systems. For example, individuals with anterior
uveitis are usually tested for the HLA-B27 gene, syphilis (with specific and non-specific
treponema serologies), and lung pathology (with a chest x-ray or computed tomography
(CT) to evaluate for sarcoidosis, tuberculosis, ect.). In intermediate uveitis, focus is also
given to the presence of neurologic symptoms that could suggest multiple sclerosis and
prompt an MRI. Additional testing in posterior uveitis depends on the presentation (retinitis,
choroiditis, retinochoroiditis, vasculitis) as each of these entities has its own differential
diagnosis.
Author Manuscript

5. Discussion of some causes of uveitis in the elderly

The most common type of uveitis in the elderly, as it is in the general population, is anterior
uveitis, followed by panuveitis and posterior uveitis.1 One review article summarized the
most common causes of uveitis in the elderly derived from 10 studies conducted in 8
countries (Table 1).1 This article will discuss two of the most common diagnoses found in
the latter review (herpes simplex virus (HSV) and sarcoidosis) along with other causes of

Drugs Aging. Author manuscript; available in PMC 2019 May 01.

 Akinsoji et al. Page 6

uveitis (ocular ischemic syndrome and CNS lymphoma) that should be considered in the
Author Manuscript

elderly. Although uveitis can first occur after 60 years of age, it is possible that the
inflammatory process may have begun at an earlier time, continuing after the age of 60.
Other etiologies, including HLA-B27 associated disease and other common causes of
uveitis, may be the underlying causes of inflammation. A wide differential must thus be
entertained when evaluating a patient with uveitis, regardless of age.

3.1 Anterior uveitis in the elderly

Anterior chamber inflammation is the most common location for uveitis in the elderly,1,32
with acute anterior uveitis being the most common sub-type (as opposed to chronic anterior
uveitis). Two notable causes of anterior uveitis in the elderly population are herpetic uveitis
and ocular ischemia.
Author Manuscript

A. Herpetic uveitis—Herpetic uveitis can affect all layers of the eye but most commonly
presents with anterior uveitis. Herpetic disease is the most common cause of infectious
uveitis, the top culprits being herpes simplex virus (HSV) and varicella-zoster virus (VZV).
Herpetic uveitis makes up 90% of infectious uveitis cases seen by community
ophthalmologists, often affecting patients of working age.33 At autopsy, HSV is found in the
trigeminal ganglion in almost 100% of individuals over age 60 years and is the most
frequent cause of herpetic uveitis.34 HSV is a double stranded DNA virus, categorized into 2
groups based on specific viral antigens (HSV I and II). HSV I most often affects the
oropharyngeal region while HSV II most often affects the genital region; however, they can
overlap. The primary manifestation of HSV in the eye is a blepharoconjunctivitis. Herpetic
uveitis is thought to result from disruption of latency after which the virus travels up sensory
axons and reactivates in the eye. Reported risk factors for viral reactivation are
immunosuppression, stress, and sunlight.35
Author Manuscript

Patients with herpetic uveitis may complain of blurry vision due to concomitant corneal
disease (scarring/edema), photophobia, eye pain, and/or headache. Some individuals with
recurrent episodes of HSV do not report pain due to virally-mediated trigeminal nerve
damage. Iritis associated with HSV is usually unilateral and may or may not have corneal
involvement, such as keratitis or corneal edema. Multiple studies have reported iris atrophy
and a distorted pupil in many patients (Figure 1).36 Herpetic uveitis is commonly
accompanied by high intra-ocular pressure (IOP). The elevated IOP can occur from
inflammation of the trabecular meshwork, posterior synechiae (the adherence of the iris to
either the cornea or lens), and/or sensitivity to topical steroids. The keratic precipitates
associated with herpetic uveitis are often pigmented and located inferiorly on the cornea.37
Author Manuscript

Herpetic uveitis is primarily treated with topical corticosteroids as the pathophysiology is

believed to be an immune-mediated response to the virus. The Herpetic Eye Disease Study
(HEDS) assessed the benefit of adding oral acyclovir to a regimen of topical prednisolone
phosphate and trifluridine for the treatment HSV uveitis. This was a multi-centered trial that
randomly assigned patients to a 10-week course of oral acyclovir 400 milligrams 5 times
daily or oral placebo in conjunction with topical trifluridine and a topical corticosteroid.
Treatment failure was defined as a persistence or worsening of ocular inflammation,

Drugs Aging. Author manuscript; available in PMC 2019 May 01.

 Akinsoji et al. Page 7

withdrawal of medication because of toxicity, or a request by the patient to withdraw from

Author Manuscript

the trial for any reason. Treatment failure occurred in 11 (50%) of 22 patients in the
acyclovir group and in 19 (68%) of 28 patients in the placebo group. While this difference
did not reach statistical significance, there was a trend that suggested a benefit of oral
acyclovir.38 In reality, topical antivirals are not used to treat individuals with HSV uveitis
without active keratitis; systemic antivirals are often used concomitantly with topical
corticosteroids. Uveitis complications also need to be treated, and IOP lowering medications
are often needed either acutely or chronically. Fortunately, treatment of inflammation
typically leads to a decrease in IOP in these patients.

Herpetic disease can also manifest in the retina as acute retinal necrosis (ARN). This entity
is more commonly seen the elderly compared to younger individuals.39 HSV I and varicella-
zoster virus (VZV) more common causes of ARN in the older populations, while HSV2 is
more common in younger populations.39 ARN can masquerade as an anterior uveitis, and it
Author Manuscript

is thus important to perform a detailed dilated fundus examination in all patients with
uveitis. Unlike HSV anterior uveitis, ARN presents bilaterally in about 66% of patients.39
Symptoms of ARN include ocular pain, decreased visual acuity, floaters, and photophobia.39
ARN progresses quickly and rapid diagnosis and treatment are needed. Even with prompt
treatment, patients are at risk for retinal detachment arising from areas of retinal atrophy.39
Treatment involves intravitreal, oral, and/or intravenous antivirals; corticosteroids are often
used concomitantly to treat inflammation.39

B. Ocular ischemic syndrome (OIS)—Ocular ischemia can lead to anterior and

posterior-segment ischemia, and one of its manifestations can be anterior uveitis.40 Ocular
ischemia is a condition caused by stenosis or blockage of either the common or internal
carotid artery. The ophthalmic artery, a branch of the internal carotid artery, supplies the
Author Manuscript

orbital structures of the eye. Any type of occlusion of the carotid arteries can result in
decreased blood supply to the orbital structures which can lead to visual loss. A complete
occlusion of the carotid artery is seen in about 50% of all patients with ocular ischemic
syndrome.41 More men are affected by ocular ischemia than women, partially explained by
the higher rates of atherosclerosis in men.41 Pre-existing ipsilateral carotid stenosis can be
found in more than 90% of patients with OIS.42 This condition usually occurs in patients
over 65 years of age, and it is uncommon in patients under 50. It should always be suspected
in elderly patients with asymmetric anterior uveitis, hypotony, neovascularization, cataract,
and retinopathy.

The most common manifestation of OIS is transient or permanent vision loss. A mild
anterior uveitis (trace cell and flare) is present in approximately 20% of affected individuals.
Author Manuscript

41 The presence of ocular ischemia is an indicator of systemic ischemic disease and

treatment includes systemic management of vascular risk factors. A carotid ultrasound

should be performed in these patients and based on the findings, endarterectomy (removing
the blockage in the artery) or carotid stenting can be considered. Locally, topical
corticosteroids can be used to decrease anterior segment inflammation, as needed. Iris
neovascularization is also seen in OIS and should be evaluated and treated, since 90% or
more of patient who develop neovascular glaucoma become legally blind.42 Posterior
segment ischemic findings are present in almost all patients and include narrowing of the

Drugs Aging. Author manuscript; available in PMC 2019 May 01.

 Akinsoji et al. Page 8

retinal arteries and dilated retinal veins. Midperipheral intraretinal hemorrhages are present
Author Manuscript

in about 80% of the patients (Figure 2).

3.2 Posterior and panuveitis in the elderly

One common cause of posterior and panuveitis in the elderly is ocular sarcoidosis. Central
nervous system lymphoma, while not common, must be considered in older individuals as it
can masquerade as a posterior and panuveitis.

A. Ocular sarcoidosis—Sarcoidosis is a leading cause of ocular inflammation and non-

caseating granulomas can affect all parts of the eye as well as other organs. Specifically,
sarcoidosis can present in the eye as a conjunctivitis, scleritis, uveitis, and/or orbital
inflammation. The most common presentation is a bilateral granulomatous uveitis seen in
20%–60% of individuals with sarcoidosis.43–45 The HLA-DRB1 locus was found to be a
Author Manuscript

significant risk factor for sarcoidosis, and the allele HLA-DRB1*0401 was associated with
ocular involvement in both blacks and whites (odds ratio 3.49).43,46 Sarcoidosis has a
bimodal peak age of presentation of 20 to 30 years and 50 to 60 years.43 Blacks are more
likely to develop the disease at a younger age than whites (35 to 44 vs. 43 to 52 years).43
Women are more frequently affected than men.43 The pathophysiology of sarcoidosis
involves the interplay of macrophages, dendritic cells, B cells, and T-helper cells,
particularly Th1.47 Th1 cells release cytokines like IFNϫ that promote macrophage
accumulation which are responsible for the formation of granulomas.47

Ocular sarcoidosis can present with findings both in the anterior (cornea, iris, ciliary body,
and/or lens) and posterior (vitreous humor, retina, choroid, and/or optic nerve) segments of
the eye. Anterior chamber inflammation is a common finding in sarcoid uveitis (91% in one
study48) both with and without posterior segment findings.43 Mutton-fat keratic precipitates,
Author Manuscript

iris nodules or both are present in about 46%.44 Vitritis (Figure 3A) with snowballs or string
of pearls can be found in approximately 50% of patients. Posterior uveitis in sarcoidosis is
usually bilateral and typically manifests with choroidal inflammation.43 Choroidal
granulomas can present as unifocal or multifocal spots, and centrally or peripherally.44
Many times, punched out choroidal lesions are seen representing inactive choroidal disease
(Figure 3B). Perivascular exudates along retinal veins can be seen in severe forms and have
been described as “candle-wax drippings.49 Leakage is often seen on fluorescein
angiography from midperipheral vessels typically without vascular occlusion.43

Sarcoid uveitis is typically a chronic condition; and ocular complications such as cystoid
macular edema, vitreous opacities, and glaucoma are well-recognized complications of
sarcoid uveitis, with the former two being major causes of vision decrease in patients with
Author Manuscript

sarcoid intermediate uveitis.43 Currently there is no definitive diagnostic test for sarcoidosis
other than a biopsy. The advancement of imaging technology has allowed for useful non-
invasive imaging of the choroid and retina in cross-section, offering insights into the
underlying diagnosis and helping to differentiate between an autoimmune granulomatous
disease like sarcoidosis from an infectious granulomatous uveitis like tuberculosis. Sattler’s
medium-sized vessel choroidal layer appears disproportionally enlarged in sarcoid compared
with tuberculous uveitis on enhanced depth optical coherence tomography imaging.50

Drugs Aging. Author manuscript; available in PMC 2019 May 01.

 Akinsoji et al. Page 9

Management of ocular sarcoidosis depends on the area of the eye affected and the severity of
Author Manuscript

inflammation. Systemically, anti-tumor necrosis factor alpha (TNF-α) agents (e.g.

adalimumab (Humira™, AbbVie, Mettawa, Illinois)) have become first line agents for the
disease.51 Locally, anterior uveitis can be managed with topical corticosteroids, while
intermediate and posterior uveitis can be treated with intravitreal corticosteroid injections or
longer acting depot, as needed. Typically, a combination of systemic and local therapy is
used to manage inflammation with the goal being total control of inflammation and minimal
side effects (local and systemic) from therapy. Imaging can be used to monitor response to
treatment since the choroid appears to be thicker in active granulomatous uveitis. Imaging
can also be used to demonstrate resolution of the lesions.50

B. Central nervous system (CNS) lymphoma—CNS lymphoma can masquerade as a

bilateral intermediate, posterior, and pan- uveitis. It is most commonly caused by high-grade
non-Hodgkin lymphoma, with the tumor arising from B cells.52,53 Major risk factors for this
Author Manuscript

disease are immunodeficiency and advancing age.54 The age of peak incidence for this
lymphoma is around 75 to 84 years.52 Asians are more likely to be affected than blacks and
whites. Though incidence is higher among men than women, women are more likely to
present with intraocular involvement compared to men.52,53,55 Fifteen to twenty five percent
of individuals diagnosed with CNS lymphoma have intraocular involvement, approximately
half of which had eye involvement as the presenting feature of the disease.56,57

The typical clinical profile is an elderly patient with treatment refractory uveitis. The
posterior segment of the eye, particularly the vitreous and the uvea, are common sites of
involvement.56 On examination, findings are typically bilateral but can be asymmetric.
Circulating tumor cells can appear in the anterior chamber in as many as 75% of patients and
occasionally settle into a pseudo-hypopyon formation. The keratic precipitates in PCNSL
Author Manuscript

typically have a branching appearance, and the vitritis appears as coarse, clumped cells
which are a mix of reactive lymphocytes and malignant lymphocytes.58 The most distinct
feature of PCNSL is low-lying, yellow-whitish lesions deep in the sensory retina (Figure 4).
They can be single, multiple, confluent, or discrete. Subretinal pigment epithelium infiltrates
due to the accumulation of atypical lymphocytes are found beneath the RPE and optic nerve.
These atypical lymphocytes can also accumulate within or around retinal vessels,
compromising vasculature and giving a clinical aspect of an ischemic retinopathy or viral
retinitis.

The optimal management of CNS lymphoma with intraocular involvement remains

controversial. It is often systemic, as sub-clinical CNS disease is suspected even in patients
with isolated ocular manifestations. Locally, therapies that have been described include
Author Manuscript

external beam radiation59 and intravitreal chemotherapy.60

6. Challenges in treating the elderly

6.1 Polypharmacy in elderly
Treatment of the different types of uveitis can include both local and systemic medications.
The elderly are a special population because they are often on multiple medications,
including “aspirin, anti-hypertensives, and statins”61 in addition to systemic medications

Drugs Aging. Author manuscript; available in PMC 2019 May 01.

 Akinsoji et al. Page 10

they may be using to treat uveitis. Therefore, there is a need to consider the resulting multi-
Author Manuscript

drug interactions that occur in the elderly.

Along with an increased number of total medications, there are also changes in drug
pharmacokinetics (the movement of a drug throughout the body) and pharmacodynamics
(effects of a drug on the body) with age. Regarding pharmacokinetics, with age, blood flow
to the liver decreases. There is decreased liver mass, with a subsequent decrease in the
amount of drug that can be metabolized.61 Drug metabolism is important because it not only
helps prevent drug toxicity, but also marks harmful substances for renal excretion.
Unfortunately, renal clearance also decreases with age61; and drugs stay in the bloodstream
longer and may accumulate if inappropriate dosing is given. Regarding pharmacodynamics,
drugs may be more effective in the elderly because of lessened regulatory functions (e.g. risk
of postural hypotension after taking anti-hypertensives).61 Eye care professionals must take
into consideration the challenges of polypharmacy in the elderly and ensure that the doses
Author Manuscript

for systemic medications result in benefit with the least amount of harm.

6.2 Adherence
Nonadherence is another challenge faced by health professionals. One explanation for
nonadherence is a lack of or inadequate health literacy.62 Adherence can be improved by
taking time to ensure that the patient understands why they are using medications as well as
clear instructions on how to use them. Another barrier to adherence is cognitive, hearing,
and/or vision impairment which is common in the elderly.62 Health professionals should ask
whether individuals need someone to assist them in taking medication. Another challenge
comes from side effects or adverse reactions.62 If nonadherence is an issue, it is imperative
that health professionals inquire about the reasons for nonadherence. This discussion may
lead to alternative therapies that are more acceptable and/or comfortable for the patient.
Author Manuscript

Conclusions
Uveitis is a group of inflammatory conditions of the eye that have various underlying causes
and various clinical manifestations. Certain types of uveitis are more common in the elderly
and this may be attributed to age-related risk factors such as immunosenescence
(predisposing the elderly to infectious uveitis and cancer) and inflammaging (predisposing
the elderly to non-infectious uveitis). Eye care professionals should approach all patients
with uveitis with a wide differential, obtaining the appropriate history and clinical
examination to arrive at the correct diagnosis. Management of uveitis varies based on the
underlying etiology, disease manifestations, and structural complications. Treatment options
for uveitis include systemic drugs, which raise challenges regarding drug interactions in a
Author Manuscript

population that is likely on multiple medications already. Eye care professionals must work
with their patients as partners to increase education, manage side effects, and examine
possible reasons for nonadherence to help achieve optimal patient outcomes.

Acknowledgments
Financial support:

Drugs Aging. Author manuscript; available in PMC 2019 May 01.

 Akinsoji et al. Page 11

Supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and
Development, Clinical Sciences Research EPID-006-15S (Dr. Galor), R01EY026174 (Dr. Galor), NIH Center Core
Author Manuscript

Grant P30EY014801 and Research to Prevent Blindness Unrestricted Grant.

Bibliography
1. Abdulaal MR, Abiad BH, Hamam RN. Uveitis in the Aging Eye: Incidence, Patterns, and
Differential Diagnosis. Journal of ophthalmology. 2015; 2015:509456. [PubMed: 26090218]
2. Facts About Uveitis. National Eye Institute. 2018. at https://nei.nih.gov/health/uveitis/uveitis.)
3. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature Working G.
Standardization of uveitis nomenclature for reporting clinical data. Results of the First International
Workshop. Am J Ophthalmol. 2005; 140:509–16. [PubMed: 16196117]
4. Gupta R, Murray PI. Chronic non-infectious uveitis in the elderly: epidemiology, pathophysiology
and management. Drugs & aging. 2006; 23:535–58. [PubMed: 16930083]
5. Intermediate Uveitis in Children. American Academy of Ophthalmology. 2016. at https://
www.aao.org/eyenet/article/intermediate-uveitis-in-children.)
Author Manuscript

6. Rossi DJ, Bryder D, Weissman IL. Hematopoietic stem cell aging: Mechanism and consequence.
Experimental Gerontology. 2007; 42:385–90. [PubMed: 17275237]
7. Lesourd B, Mazari L. Nutrition and immunity in the elderly. The Proceedings of the Nutrition
Society. 1999; 58:685–95. [PubMed: 10604204]
8. Guidi N, Sacma M, Ständker L, et al. Osteopontin attenuates aging‐associated phenotypes of
hematopoietic stem cells. The EMBO Journal. 2017
9. Ventura MT, Casciaro M, Gangemi S, Buquicchio R. Immunosenescence in aging: between immune
cells depletion and cytokines up-regulation. Clinical and Molecular Allergy. 2017; 15:21. [PubMed:
29259496]
10. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from
infancy to old age. Proceedings of the Royal Society B: Biological Sciences. 2015:282.
11. Wulf HC, Sandby-Møller J, Kobayasi T, Gniadecki R. Skin aging and natural photoprotection.
Micron. 2004; 35:185–91. [PubMed: 15036273]
12. Chandra RK. Nutrition and immunity in the elderly. Nutrition reviews. 1992; 50:367–71. [PubMed:
1488169]
Author Manuscript

13. Malek TR. The main function of IL‐2 is to promote the development of T regulatory cells. Journal
of Leukocyte Biology. 2003; 74:961–5. [PubMed: 12960253]
14. The origins of memory T cells. Nature, 2017. 2018. at https://www.nature.com/articles/
d41586-017-08280-8.)
15. Effector CD8 T cells dedifferentiate into long-lived memory cells. Nature, 2017. 2018. at https://
www.nature.com/articles/nature25144.)
16. Boyman O, Cho JH, Sprent J. The role of interleukin-2 in memory CD8 cell differentiation.
Advances in experimental medicine and biology. 2010; 684:28–41. [PubMed: 20795538]
17. Salam N, Rane S, Das R, et al. T cell ageing: Effects of age on development, survival & function.
The Indian Journal of Medical Research. 2013; 138:595–608. [PubMed: 24434315]
18. Woodland DL, Kohlmeier JE. Migration, maintenance and recall of memory T cells in peripheral
tissues. Nature reviews Immunology. 2009; 9:153–61.
19. Haynes L, Eaton SM, Burns EM, Randall TD, Swain SL. CD4 T cell memory derived from young
naive cells functions well into old age, but memory generated from aged naive cells functions
Author Manuscript

poorly. Proceedings of the National Academy of Sciences. 2003; 100:15053–8.

20. Forthal DN. Functions of Antibodies. Microbiology spectrum. 2014; 2:1–17.
21. Boren E, Gershwin ME. Inflamm-aging: autoimmunity, and the immune-risk phenotype.
Autoimmunity Reviews. 2004; 3:401–6. [PubMed: 15288008]
22. Attanasio R, Brasky KM, Robbins SH, Jayashankar L, Nash RJ, Butler TM. Age-related
autoantibody production in a nonhuman primate model. Clinical and experimental immunology.
2001; 123:361–5. [PubMed: 11298120]

Drugs Aging. Author manuscript; available in PMC 2019 May 01.

 Akinsoji et al. Page 12

23. Franceschi C, Campisi J. Chronic Inflammation (Inflammaging) and Its Potential Contribution to
Age-Associated Diseases. The Journals of Gerontology: Series A. 2014; 69:S4–S9.
Author Manuscript

24. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas Ligand-Induced Apoptosis as a
Mechanism of Immune Privilege. Science. 1995; 270:1189–92. [PubMed: 7502042]
25. Ghasemi H. Roles of IL-6 in Ocular Inflammation: A Review. Ocular immunology and
inflammation. 2018; 26:37–50. [PubMed: 28146368]
26. Michaud M, Balardy L, Moulis G, et al. Proinflammatory cytokines, aging, and age-related
diseases. Journal of the American Medical Directors Association. 2013; 14:877–82. [PubMed:
23792036]
27. Mau T, Yung R. Adipose tissue inflammation in aging. Experimental Gerontology. 2018; 105:27–
31. [PubMed: 29054535]
28. Busso N, So A. Gout. Mechanisms of inflammation in gout. Arthritis Research & Therapy. 2010;
12:206. [PubMed: 20441605]
29. Stacy S, Krolick KA, Infante AJ, Kraig E. Immunological memory and late onset autoimmunity.
Mechanisms of Ageing and Development. 2002; 123:975–85. [PubMed: 12044946]
30. Hylkema HA. The role of the immune system in uveitis induced in animals. Documenta
Author Manuscript

ophthalmologica Advances in ophthalmology. 1988; 70:339–51. [PubMed: 3075176]

31. Ildefonso CJ, Biswal MR, Ahmed CM, Lewin AS. The NLRP3 Inflammasome and its Role in
Age-Related Macular Degeneration. Advances in experimental medicine and biology. 2016;
854:59–65. [PubMed: 26427394]
32. Reeves SW, Sloan FA, Lee PP, Jaffe GJ. Uveitis in the elderly: epidemiological data from the
National Long-term Care Survey Medicare Cohort. Ophthalmology. 2006; 113:307.e1. [PubMed:
16406541]
33. Hoeksema L, Los LI. Vision-related quality of life in herpetic anterior uveitis patients. PloS one.
2014; 9:e85224. [PubMed: 24392164]
34. Foster, CS., Vitale, Albert T. Diagnosis and Treatment of Uveitis. Jaypee Highlights Medical
Publishers, Inc; 2013.
35. Herpes Simplex Virus Keratitis. American Academy of Ophthalmology (Eye Wiki). 2017. at http://
eyewiki.aao.org/Herpes_simplex_uveitis.)
36. Nalcacioglu-Yüksekkaya P, Ozdal PC, Teke MY, Kara C, Ozturk F. Presumed herpetic anterior
Author Manuscript

uveitis: a study with retrospective analysis of 79 cases. European journal of ophthalmology. 2013;
24:14–20. [PubMed: 23813111]
37. Anwar Z, Galor A, Albini TA, Miller D, Perez V, Davis JL. The diagnostic utility of anterior
chamber paracentesis with polymerase chain reaction in anterior uveitis. Am J Ophthalmol. 2013;
155:781–6. [PubMed: 23415597]
38. A controlled trial of oral acyclovir for iridocyclitis caused by herpes simplex virus. The Herpetic
Eye Disease Study Group. Arch Ophthalmol. 1996; 114:1065–72. [PubMed: 8790090]
39. Bonfioli AA, Eller AW. Acute Retinal Necrosis. Seminars in Ophthalmology. 2005; 20:155–60.
[PubMed: 16282149]
40. Brown GC, Magargal LE. The ocular ischemic syndrome. Clinical, fluorescein angiographic and
carotid angiographic features. International ophthalmology. 1988; 11:239–51. [PubMed: 3182177]
41. Terelak-Borys B, Skonieczna K, Grabska-Liberek I. Ocular ischemic syndrome - a systematic
review. Medical science monitor: international medical journal of experimental and clinical
research. 2012; 18:Ra138–44. [PubMed: 22847215]
Author Manuscript

42. Magargal LE, Sanborn GE, Zimmerman A. Venous stasis retinopathy associated with embolic
obstruction of the central retinal artery. Journal of clinical neuro-ophthalmology. 1982; 2:113–8.
[PubMed: 6226693]
43. Pasadhika S, Rosenbaum JT. Ocular Sarcoidosis. Clinics in chest medicine. 2015; 36:669–83.
[PubMed: 26593141]
44. Acharya NR, Browne EN, Rao N, Mochizuki M. Distinguishing Features of Ocular Sarcoidosis in
an International Cohort of Uveitis Patients. Ophthalmology. 2018; 125:119–26. [PubMed:
28823384]

Drugs Aging. Author manuscript; available in PMC 2019 May 01.

 Akinsoji et al. Page 13

45. Kefella H, Luther D, Hainline C. Ophthalmic and neuro-ophthalmic manifestations of sarcoidosis.

Current opinion in ophthalmology. 2017; 28:587–94. [PubMed: 28759560]
Author Manuscript

46. Rossman MD, Thompson B, Frederick M, et al. HLA-DRB1*1101: a significant risk factor for
sarcoidosis in blacks and whites. American journal of human genetics. 2003; 73:720–35.
[PubMed: 14508706]
47. Pathology and pathogenesis of sarcoidosis. 2017. at https://www.uptodate.com/contents/pathology-
and-pathogenesis-of-sarcoidosis.)
48. Crick RP, Hoyle C, Smellie H. THE EYES IN SARCOIDOSIS. The British journal of
ophthalmology. 1961; 45:461–81. [PubMed: 18170695]
49. Gould H, Kaufman HE. Sarcoid of the fundus. Archives of ophthalmology (Chicago, Ill: 1960).
1961; 65:453–6.
50. Mehta H, Sim DA, Keane PA, et al. Structural changes of the choroid in sarcoid- and tuberculosis-
related granulomatous uveitis. Eye (London, England). 2015; 29:1060–8.
51. Baughman RP, Lower EE, Ingledue R, Kaufman AH. Management of ocular sarcoidosis.
Sarcoidosis, vasculitis, and diffuse lung diseases: official journal of WASOG. 2012; 29:26–33.
52. Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma: a report from an
Author Manuscript

International Primary Central Nervous System Lymphoma Collaborative Group symposium. The
oncologist. 2011; 16:1589–99. [PubMed: 22045784]
53. Coupland SE, Heimann H, Bechrakis NE. Primary intraocular lymphoma: a review of the clinical,
histopathological and molecular biological features. Graefe’s Archive for Clinical and
Experimental Ophthalmology. 2004; 242:901–13.
54. Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in
incidence and survival in primary CNS lymphoma. British Journal of Cancer. 2011; 105:1414–8.
[PubMed: 21915121]
55. Moslehi R, Devesa SS, Schairer C, Fraumeni JF Jr. Rapidly increasing incidence of ocular non-
hodgkin lymphoma. Journal of the National Cancer Institute. 2006; 98:936–9. [PubMed:
16818858]
56. Clinical presentation, pathologic features, and diagnosis of primary central nervous system
lymphoma. 2017. 2017, at https://www.uptodate.com/contents/clinical-presentation-pathologic-
features-and-diagnosis-of-primary-central-nervous-system-lymphoma?
Author Manuscript

source=search_result&search=ocularlymphoma&selectedTitle=1~150#H8.)
57. Jahnke K, Thiel E, Abrey LE, Neuwelt EA, Korfel A. Diagnosis and management of primary
intraocular lymphoma: an update. Clinical ophthalmology (Auckland, NZ). 2007; 1:247–58.
58. Akpek EK, Ahmed I, Hochberg FH, et al. Intraocular-central nervous system lymphoma: clinical
features, diagnosis, and outcomes. Ophthalmology. 1999; 106:1805–10. [PubMed: 10485554]
59. Teckie S, Yahalom J. Primary intraocular lymphoma: treatment outcomes with ocular radiation
therapy alone. Leuk Lymphoma. 2014; 55:795–801. [PubMed: 23822539]
60. Ma WL, Hou HA, Hsu YJ, et al. Clinical outcomes of primary intraocular lymphoma patients
treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection.
Ann Hematol. 2016; 95:593–601. [PubMed: 26732884]
61. Cantlay DA, Glyn DT, Barton DN. Polypharmacy in the elderly. InnovAiT. 2016; 9:69–77.
62. MacLaughlin EJ, Raehl CL, Treadway AK, Sterling TL, Zoller DP, Bond CA. Assessing
Medication Adherence in the Elderly. Drugs & aging. 2005; 22:231–55. [PubMed: 15813656]
Author Manuscript

Drugs Aging. Author manuscript; available in PMC 2019 May 01.

 Akinsoji et al. Page 14

Key Points
Author Manuscript

• Uveitis is an inflammatory condition that can present in different locations in

the eye and can have various etiologies.

• A decline in effective immunological function that occurs with aging (e.g.

decreased ability to fight infection, imbalance of inflammatory mediators)
likely contributes to the elderly’s susceptibility to uveitis.

• Eye doctors need to consider the epidemiology and the different clinical
profiles of uveitis in their differential diagnoses as well as take into
consideration the challenges of polypharmacy and nonadherence when
determining treatment.
Author Manuscript
Author Manuscript
Author Manuscript

Drugs Aging. Author manuscript; available in PMC 2019 May 01.

 Akinsoji et al. Page 15
Author Manuscript
Author Manuscript

Figure 1.
Slit lamp photograph depicting iris atrophy in an individual with herpes simplex virus
Author Manuscript

associated chronic iritis.

Author Manuscript

Drugs Aging. Author manuscript; available in PMC 2019 May 01.

 Akinsoji et al. Page 16
Author Manuscript
Author Manuscript

Figure 2.
Fundus photograph depicting mid-peripheral hemorrhages and narrowed arteries in an
individual with ocular ischemic syndrome.
Author Manuscript
Author Manuscript

Drugs Aging. Author manuscript; available in PMC 2019 May 01.

 Akinsoji et al. Page 17
Author Manuscript
Author Manuscript

Figure 3.
Fundus photograph depicting (A) vitreous haze (arrow) in the setting of vitritis in an
individual with sarcoidosis and (B) punched out peripheral choroidal lesions representing
inactive disease.
Author Manuscript
Author Manuscript

Drugs Aging. Author manuscript; available in PMC 2019 May 01.

 Akinsoji et al. Page 18
Author Manuscript
Author Manuscript

Figure 4.
Fundus photograph depicting multifocal, creamy, sub-retinal lesions (arrow) in an individual
Author Manuscript

with primary central nervous system lymphoma.

Author Manuscript

Drugs Aging. Author manuscript; available in PMC 2019 May 01.

 Akinsoji et al. Page 19

Table

Summary of studies evaluating the most common diagnoses of uveitis in the elderly, reproduced from
Author Manuscript

Abdulaal 2015.

Study Most Common Second Most Common Third Most Common

Lebanon 2014 Idiopathic uveitis (5/18) Herpes simplex virus (5/18) Tuberculosis (3/18)

Colombia 2019 Toxoplasmosis (10/55) Idiopathic uveitis (9/55) Herpes Simplex virus (5/55)

Saudi Arabia 2009 Acute anterior uveitis (14/51) Herpes simplex virus (8/51) Tuberculosis (7/15)

Turkey 2005 Idiopathic uveitis (34/50) Herpes simplex virus (3/50) Sarcoidosis (2/50)

Japan 2005 Idiopathic uveitis (53/82) Sarcoidosis (9/82) Herpes simplex virus (7/82)

France 2003 Idiopathic uveitis (40/80) Herpes simplex virus/Varicella zoster virus Birdshot (10/80)
(10/80)

Saudi Arabia 2002 Acute anterior uveitis (5/18) Tuberculosis (5/18) Herpes simplex virus (3/18)

France 2002 Idiopathic uveitis (5/19) Sarcoidosis (3/19) Lymphoma (2/19)

Author Manuscript

United States 1998 Idiopathic uveitis (43/138) HSV (16/138) Sarcoidosis (11/138)

Finland 1994 Acute anterior uveitis (118/191) Idiopathic uveitis (21/191) Sarcoidosis (2/191)

United Kingdom 1994 Idiopathic uveitis (55/71) Insulin dependent diabetes mellitus (5/71) Sarcoidosis (3/71)
Author Manuscript
Author Manuscript

Drugs Aging. Author manuscript; available in PMC 2019 May 01.